Abstract 43P
Background
Breast cancer remains a significant concern worldwide. Risk-based screening, which tailors screening recommendations to individual risk levels, has been shown to enhance patient stratification. However, most research on model development focuses on Western populations, leaving the predictive accuracy of these models for Southeast Asian populations largely uncharacterized.
Methods
We conducted an observational case-control study comprising 305 Indonesian women to assess the applicability of published risk models to the local population. We employed a combined risk model to classify patients as either elevated or average risk. Our combined model evaluates two separate risk factors: genetic risk, assessed using ancestry-adjusted PRS scores based on the Mavaddat model, and clinical risk, evaluated using the Gail model. The performance of each individual model and their combined effectiveness were analyzed using the Area Under the Curve (AUC) and Odds Ratio (OR).
Results
Individual risk models retained their predictive efficacy in the Indonesian context. Specifically, the AUC achieved for genetic risk is AUC of 0.674 (p = 1.28 x 10-3; Risk group: OR = 3.16; p = 2.5 x 10-1). For clinical risk, the AUC stands at 0.674 (p = 5.16 x 10-4; Risk group: OR = 7.636; p = 6.1 x 10-3). Remarkably, when combined, the AUC increased to 0.701 (Risk group: OR= 3.897; p = 4.28 x 10-2), signifying the benefits of a multi-factor model. Based on a subset of the samples taken from this study, the Nala Breast Cancer Risk genetic risk algorithm generated higher AUC when compared to a leading third-party software that uses the same PRS model for breast cancer (0.63 vs 0.55). This improvement is primarily due to our method of translating PRS scores into categorical outcomes, which integrates localized disease incidence and mortality rates.
Conclusions
Our findings demonstrate for the first time the applicability of the Polygenic Risk Score using Mavaddat model and clinical score using Gail model to Indonesian populations. In addition, our study shows that, within this demographic, combined risk models provide a superior predictive framework compared to single-factor approaches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
NalaGenetics.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract